Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 1.075
Filtrar
Más filtros

Intervalo de año de publicación
1.
N Engl J Med ; 389(19): 1766-1777, 2023 Nov 09.
Artículo en Inglés | MEDLINE | ID: mdl-37815935

RESUMEN

BACKGROUND: Nursing home residents are at high risk for infection, hospitalization, and colonization with multidrug-resistant organisms. METHODS: We performed a cluster-randomized trial of universal decolonization as compared with routine-care bathing in nursing homes. The trial included an 18-month baseline period and an 18-month intervention period. Decolonization entailed the use of chlorhexidine for all routine bathing and showering and administration of nasal povidone-iodine twice daily for the first 5 days after admission and then twice daily for 5 days every other week. The primary outcome was transfer to a hospital due to infection. The secondary outcome was transfer to a hospital for any reason. An intention-to-treat (as-assigned) difference-in-differences analysis was performed for each outcome with the use of generalized linear mixed models to compare the intervention period with the baseline period across trial groups. RESULTS: Data were obtained from 28 nursing homes with a total of 28,956 residents. Among the transfers to a hospital in the routine-care group, 62.2% (the mean across facilities) were due to infection during the baseline period and 62.6% were due to infection during the intervention period (risk ratio, 1.00; 95% confidence interval [CI], 0.96 to 1.04). The corresponding values in the decolonization group were 62.9% and 52.2% (risk ratio, 0.83; 95% CI, 0.79 to 0.88), for a difference in risk ratio, as compared with routine care, of 16.6% (95% CI, 11.0 to 21.8; P<0.001). Among the discharges from the nursing home in the routine-care group, transfer to a hospital for any reason accounted for 36.6% during the baseline period and for 39.2% during the intervention period (risk ratio, 1.08; 95% CI, 1.04 to 1.12). The corresponding values in the decolonization group were 35.5% and 32.4% (risk ratio, 0.92; 95% CI, 0.88 to 0.96), for a difference in risk ratio, as compared with routine care, of 14.6% (95% CI, 9.7 to 19.2). The number needed to treat was 9.7 to prevent one infection-related hospitalization and 8.9 to prevent one hospitalization for any reason. CONCLUSIONS: In nursing homes, universal decolonization with chlorhexidine and nasal iodophor led to a significantly lower risk of transfer to a hospital due to infection than routine care. (Funded by the Agency for Healthcare Research and Quality; Protect ClinicalTrials.gov number, NCT03118232.).


Asunto(s)
Antiinfecciosos Locales , Infecciones Asintomáticas , Clorhexidina , Infección Hospitalaria , Casas de Salud , Povidona Yodada , Humanos , Administración Cutánea , Administración Intranasal , Antiinfecciosos Locales/administración & dosificación , Antiinfecciosos Locales/uso terapéutico , Baños , Clorhexidina/administración & dosificación , Clorhexidina/uso terapéutico , Infección Hospitalaria/epidemiología , Infección Hospitalaria/prevención & control , Infección Hospitalaria/terapia , Hospitalización/estadística & datos numéricos , Casas de Salud/estadística & datos numéricos , Transferencia de Pacientes/estadística & datos numéricos , Povidona Yodada/administración & dosificación , Povidona Yodada/uso terapéutico , Cuidados de la Piel/métodos , Infecciones Asintomáticas/terapia
2.
Z Gastroenterol ; 62(7): 1032-1041, 2024 Jul.
Artículo en Alemán | MEDLINE | ID: mdl-38976982

RESUMEN

INTRODUCTION: Clostridioides difficile infection (CDI), as a nosocomial disease, is associated with high morbidity and mortality. Even though the incidence of CDI has been declining in Germany in recent years, the individual infection may pose a medical challenge despite therapeutic advances. The aim here is to clarify which gaps practitioners consider to be particularly serious in care and in the existing evidence base. METHODS: In a moderated workshop of German CDI experts the topics considered as relevant were identified. A survey already conducted in five other countries (Australia, France, Great Britain, Canada, and Italy) was adapted and processed by 27 practitioners. During the evaluation, the topics perceived as particularly important were identified, the statements of the specialist groups were compared and changes in opinion were considered. RESULTS: 27 fully completed questionnaires were evaluated. The need for improvement was primarily seen in the prevention of CDI recurrences (74.1%) and the treatment of recurrences (55.6%). Evidence deficits were noted in the treatment of recurrences (55.6%) and identification of risk factors for recurrences (48.1%). Improving care via fecal microbiota transfer (FMT) was named by 70.4%. For guidelines, more clarity (48.1%) and more regular updates (40.7%) were desired. For patients, better education on appropriate antibiotic use (52.0%) and choice of FMT were desired (48.1%). SUMMARY: The German expert view and the international assessment is similar, when asked about the need for improvement in care and evidence gaps in the treatment of patients with CDI: The focus is on prevention and therapy of recurrent CDI. The problem of access to FMT is a German peculiarity that seems to need improvement.


Asunto(s)
Infecciones por Clostridium , Humanos , Infecciones por Clostridium/terapia , Infecciones por Clostridium/epidemiología , Alemania , Mejoramiento de la Calidad , Internacionalidad , Testimonio de Experto , Trasplante de Microbiota Fecal , Medicina Basada en la Evidencia , Evaluación de Necesidades , Infección Hospitalaria/prevención & control , Infección Hospitalaria/epidemiología , Infección Hospitalaria/terapia , Guías de Práctica Clínica como Asunto
3.
Curr Opin Anaesthesiol ; 35(5): 549-554, 2022 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-35943123

RESUMEN

PURPOSE OF REVIEW: The aim of this review is to provide a practical and updated summary on healthcare-associated central nervous system infections and their management. RECENT FINDINGS: The term 'healthcare-associated ventriculitis and meningitis' has recently been coined and clinical practical guidelines have been published on the management of these nosocomial infections. Many aspects have still to be further investigated (e.g. cerebrospinal fluid biomarkers, indications for novel antibiotics, intrathecal antimicrobial regimens). SUMMARY: Clinicians should maintain a high index of suspicion for healthcare-associated central nervous system infections in patients with specific risk factors (i.e. recent neurosurgery, cerebrospinal shunts, drains or implantable devices, head/spinal traumatic events), taking into account systemic signs, and alterations in microbiological, imaging, cerebrospinal fluid findings. The diagnosis is often difficult to confirm because of reduced levels of consciousness or coma. Both Gram-positive and Gram-negative (often multidrug-resistant or even pandrug-resistant) microorganisms may be the cause. Selection of antibiotics must consider susceptibility and penetration into the central nervous system. Ineffective treatments are frequent, and mortality can reach 60%. Future research should focus on the diagnostic performance of biomarkers and on the use of novel antimicrobial regimens, especially for the treatment of difficult to treat infections.


Asunto(s)
Infecciones del Sistema Nervioso Central , Infección Hospitalaria , Antibacterianos/uso terapéutico , Sistema Nervioso Central , Infecciones del Sistema Nervioso Central/inducido químicamente , Infecciones del Sistema Nervioso Central/diagnóstico , Infecciones del Sistema Nervioso Central/terapia , Infección Hospitalaria/diagnóstico , Infección Hospitalaria/terapia , Atención a la Salud , Humanos
5.
Crit Care Med ; 49(2): 169-187, 2021 02 01.
Artículo en Inglés | MEDLINE | ID: mdl-33438970

RESUMEN

OBJECTIVE: The first 70 years of critical care can be considered a period of "industrial revolution-like" advancement in terms of progressing the understanding and care of critical illness. Unfortunately, like the industrial revolution's impact on the environment, advancing ICU care of increasingly elderly, immunosuppressed, and debilitated individuals has resulted in a greater overall burden and complexity of nosocomial infections within modern ICUs. Given the rapid evolution of nosocomial infections, the authors provide an updated review. DATA SOURCES AND STUDY SELECTION: We searched PubMed and OVID for peer-reviewed literature dealing with nosocomial infections in the critically ill, as well as the websites of government agencies involved with the reporting and prevention of nosocomial infections. Search terms included nosocomial infection, antibiotic resistance, microbiome, antibiotics, and intensive care. DATA EXTRACTION AND DATA SYNTHESIS: Nosocomial infections in the ICU setting are evolving in multiple domains including etiologic pathogens plus novel or emerging pathogens, prevalence, host risk factors, antimicrobial resistance, interactions of the host microbiome with nosocomial infection occurrence, and understanding of pathogenesis and prevention strategies. Increasing virulence and antimicrobial resistance of nosocomial infections mandate increasing efforts toward their prevention. CONCLUSIONS: Nosocomial infections are an important determinant of outcome for patients in the ICU setting. Systematic research aimed at improving the prevention and treatment of nosocomial infections is still needed.


Asunto(s)
Cuidados Críticos/organización & administración , Enfermedad Crítica/terapia , Infección Hospitalaria/terapia , Farmacorresistencia Bacteriana , Antiinfecciosos Locales/uso terapéutico , Infección Hospitalaria/prevención & control , Humanos , Unidades de Cuidados Intensivos/organización & administración , Medición de Riesgo , Factores de Riesgo
6.
Crit Care Med ; 49(11): 1883-1894, 2021 11 01.
Artículo en Inglés | MEDLINE | ID: mdl-34259454

RESUMEN

OBJECTIVES: To describe the epidemiology of sepsis in critical care by applying the Sepsis-3 criteria to electronic health records. DESIGN: Retrospective cohort study using electronic health records. SETTING: Ten ICUs from four U.K. National Health Service hospital trusts contributing to the National Institute for Health Research Critical Care Health Informatics Collaborative. PATIENTS: A total of 28,456 critical care admissions (14,332 emergency medical, 4,585 emergency surgical, and 9,539 elective surgical). MEASUREMENTS AND MAIN RESULTS: Twenty-nine thousand three hundred forty-three episodes of clinical deterioration were identified with a rise in Sequential Organ Failure Assessment score of at least 2 points, of which 14,869 (50.7%) were associated with antibiotic escalation and thereby met the Sepsis-3 criteria for sepsis. A total of 4,100 episodes of sepsis (27.6%) were associated with vasopressor use and lactate greater than 2.0 mmol/L, and therefore met the Sepsis-3 criteria for septic shock. ICU mortality by source of sepsis was highest for ICU-acquired sepsis (23.7%; 95% CI, 21.9-25.6%), followed by hospital-acquired sepsis (18.6%; 95% CI, 17.5-19.9%), and community-acquired sepsis (12.9%; 95% CI, 12.1-13.6%) (p for comparison less than 0.0001). CONCLUSIONS: We successfully operationalized the Sepsis-3 criteria to an electronic health record dataset to describe the characteristics of critical care patients with sepsis. This may facilitate sepsis research using electronic health record data at scale without relying on human coding.


Asunto(s)
Cuidados Críticos/estadística & datos numéricos , Infección Hospitalaria/mortalidad , Puntuaciones en la Disfunción de Órganos , Sepsis/mortalidad , Sepsis/terapia , Índice de Severidad de la Enfermedad , Adulto , Anciano , Estudios de Cohortes , Infección Hospitalaria/terapia , Femenino , Humanos , Unidades de Cuidados Intensivos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Choque Séptico/mortalidad , Medicina Estatal
7.
Ann Emerg Med ; 77(1): 19-31, 2021 01.
Artículo en Inglés | MEDLINE | ID: mdl-32788066

RESUMEN

STUDY OBJECTIVE: To synthesize the evidence regarding the infection risk associated with different modalities of oxygen therapy used in treating patients with severe acute respiratory infection. Health care workers face significant risk of infection when treating patients with a viral severe acute respiratory infection. To ensure health care worker safety and limit nosocomial transmission of such infection, it is crucial to synthesize the evidence regarding the infection risk associated with different modalities of oxygen therapy used in treating patients with severe acute respiratory infection. METHODS: MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched from January 1, 2000, to April 1, 2020, for studies describing the risk of infection associated with the modalities of oxygen therapy used for patients with severe acute respiratory infection. The study selection, data extraction, and quality assessment were performed by independent reviewers. The primary outcome measure was the infection of health care workers with a severe acute respiratory infection. Random-effect models were used to synthesize the extracted data. RESULTS: Of 22,123 citations, 50 studies were eligible for qualitative synthesis and 16 for meta-analysis. Globally, the quality of the included studies provided a very low certainty of evidence. Being exposed or performing an intubation (odds ratio 6.48; 95% confidence interval 2.90 to 14.44), bag-valve-mask ventilation (odds ratio 2.70; 95% confidence interval 1.31 to 5.36), and noninvasive ventilation (odds ratio 3.96; 95% confidence interval 2.12 to 7.40) were associated with an increased risk of infection. All modalities of oxygen therapy generate air dispersion. CONCLUSION: Most modalities of oxygen therapy are associated with an increased risk of infection and none have been demonstrated as safe. The lowest flow of oxygen should be used to maintain an adequate oxygen saturation for patients with severe acute respiratory infection, and manipulation of oxygen delivery equipment should be minimized.


Asunto(s)
Infección Hospitalaria/transmisión , Transmisión de Enfermedad Infecciosa de Paciente a Profesional , Terapia por Inhalación de Oxígeno , Síndrome Respiratorio Agudo Grave/transmisión , Infección Hospitalaria/terapia , Humanos , Terapia por Inhalación de Oxígeno/efectos adversos , Factores de Riesgo , Síndrome Respiratorio Agudo Grave/terapia
8.
Clin Exp Nephrol ; 25(6): 652-659, 2021 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-33555454

RESUMEN

BACKGROUND: Blood purification therapy is a treatment method, wherein many patients gather in the same space to receive regular treatments, possibly increasing the risk of contracting the coronavirus disease 2019 (COVID-19) through contact, droplet, and aerosol. We experienced a nosocomial outbreak and evaluated the clinical characteristics of COVID-19 infection in patients undergoing blood purification therapy. METHODS: We retrospectively analyzed 28 patients who underwent blood purification therapy at the dialysis center of our hospital from April 2, 2020, to April 29, 2020. Logistic regression analysis was performed to identify clinical factors related to COVID-19 for 18 patients who were tested using real-time reverse transcriptase-polymerase chain reaction (RT-PCR). RESULTS: Of the 28 patients, seven were COVID-19 positive, as confirmed by RT-PCR. The median age was 77 years, 22 patients were male (79%), four patients had acute kidney injury (14%), and six patients were bedridden (21%). All infected patients had been admitted to the wards where the nosocomial outbreak had occurred. Logistic regression analysis revealed that being bedridden (odds ratio 13.33, 95% confidence interval 1.05-169.56, p < 0.05) was significantly related to COVID-19 infection. However, the Charlson comorbidity index, receiving dialysis in the same room, and adjacency of the dialysis bed to COVID-19-positive patients before the confirmation of infection did not reveal any significant relationship. CONCLUSION: Bedridden patients admitted to nosocomial infection wards were associated with COVID-19 infection, and transmission within the dialysis center was not observed. More rigorous infection control measures need to be implemented for bedridden patients undergoing blood purification therapy.


Asunto(s)
COVID-19/terapia , COVID-19/transmisión , Infección Hospitalaria/terapia , Infección Hospitalaria/transmisión , Unidades de Hemodiálisis en Hospital , Lesión Renal Aguda/complicaciones , Adulto , Anciano , Anciano de 80 o más Años , Estudios de Cohortes , Comorbilidad , Brotes de Enfermedades , Femenino , Hospitalización , Humanos , Control de Infecciones , Masculino , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa , Diálisis Renal , Estudios Retrospectivos
9.
Am J Emerg Med ; 45: 483-489, 2021 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-33039226

RESUMEN

OBJECTIVE: There are growing concerns regarding the lack of COVID-19 pandemic response capacity in already overwhelmed emergency departments (EDs), and lack of proper isolation facilities. This study evaluated the effectiveness of the negative pressure isolation stretcher (NPIS) and additional negative pressure isolation rooms (NPIRs) on the maintenance of emergency care capacity during the COVID-19 outbreak. METHODS: A before and after intervention study was performed between February 27, 2020 and March 31, 2020 at the ED of Chungbuk National University Hospital, Cheongju, South Korea. A total of 2455 patients who visited the ED during the study period were included. Interventions included the introduction of the NPIS and additional NPIRs in the ED. The main outcome of the study was frequency of medical cessation. Secondary outcomes were the average number of ED visits and lengths of stay. RESULTS: After the intervention, average frequency of medical cessation was significantly decreased from 1.6 times per day (range 0-4) in the pre-intervention period to 0.6 times per day (range 0-3) in the post-intervention period (p-value <0.01). On the other hand, the number of patients visiting the ED increased significantly from 67.2 persons per day (range 58-79) pre-intervention to 76.3 persons per day (range 61-88) post-intervention (p value <0.01). However, there were no statistically significant differences in the average ED length of stay across the study phases (p value = 0.50). CONCLUSIONS: This intervention may provide an effective way to prepare and meet the ED response needs of the COVID-19 pandemic.


Asunto(s)
COVID-19/terapia , Infección Hospitalaria/terapia , Servicios Médicos de Urgencia/métodos , Pandemias , Aislamiento de Pacientes/instrumentación , SARS-CoV-2 , Adulto , Anciano , Control de Enfermedades Transmisibles , Comorbilidad , Infección Hospitalaria/epidemiología , Servicio de Urgencia en Hospital , Diseño de Equipo , Femenino , Humanos , Masculino , Persona de Mediana Edad , República de Corea/epidemiología , Estudios Retrospectivos
10.
Isr Med Assoc J ; 23(10): 615-617, 2021 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-34672440

RESUMEN

BACKGROUND: Patients with severe coronavirus disease-2019 (COVID-19) are susceptible to superimposed infections. OBJECTIVES: To describe COVID-19 patients who presented with complications due to Candida bloodstream co-infection (candidemia) and their outcome in a single center in northern Israel (Emek Medical Center) during the second outbreak of COVID-19 in Israel (15 June 2020 to 20 September 2020). METHODS: A retrospective study of COVID-19 patients presenting with candidemia was conducted, including clinical and laboratory data. The incidence of candidemia among hospitalized COVID-19 patients was compared to a historical cohort of non-COVID-19 controls. RESULTS: Three COVID-19 patients complicated with candidemia were documented. All three patients died shortly after the detection of candidemia. Three different Candida sp. were isolated from the blood cultures: C. albicans, C. parapsilosis, and C. glabrata. The incidence of candidemia among COVID-19 patients was 0.679 episodes per 1000 hospital days. CONCLUSIONS: Our small sample suggests a much higher incidence of candidemia among COVID-19 patients compared to a historical cohort of non-COVID-19 controls. All clinicians treating COVID-19 patients in GICU should be aware of this complication.


Asunto(s)
COVID-19 , Candida/aislamiento & purificación , Candidemia , Caspofungina/administración & dosificación , Coinfección , Infección Hospitalaria , Anciano , Antifúngicos/administración & dosificación , COVID-19/complicaciones , COVID-19/fisiopatología , COVID-19/terapia , Candidemia/complicaciones , Candidemia/diagnóstico , Candidemia/tratamiento farmacológico , Cateterismo Venoso Central/métodos , Coinfección/diagnóstico , Coinfección/microbiología , Coinfección/terapia , Cuidados Críticos/métodos , Infección Hospitalaria/diagnóstico , Infección Hospitalaria/microbiología , Infección Hospitalaria/terapia , Resultado Fatal , Femenino , Hospitalización/estadística & datos numéricos , Humanos , Masculino , Respiración Artificial/métodos , SARS-CoV-2/aislamiento & purificación , Índice de Severidad de la Enfermedad
11.
Molecules ; 26(7)2021 Mar 26.
Artículo en Inglés | MEDLINE | ID: mdl-33810292

RESUMEN

Biofilms play an essential role in chronic and healthcare-associated infections and are more resistant to antimicrobials compared to their planktonic counterparts due to their (1) physiological state, (2) cell density, (3) quorum sensing abilities, (4) presence of extracellular matrix, (5) upregulation of drug efflux pumps, (6) point mutation and overexpression of resistance genes, and (7) presence of persister cells. The genes involved and their implications in antimicrobial resistance are well defined for bacterial biofilms but are understudied in fungal biofilms. Potential therapeutics for biofilm mitigation that have been reported include (1) antimicrobial photodynamic therapy, (2) antimicrobial lock therapy, (3) antimicrobial peptides, (4) electrical methods, and (5) antimicrobial coatings. These approaches exhibit promising characteristics for addressing the impending crisis of antimicrobial resistance (AMR). Recently, advances in the micro- and nanotechnology field have propelled the development of novel biomaterials and approaches to combat biofilms either independently, in combination or as antimicrobial delivery systems. In this review, we will summarize the general principles of clinically important microbial biofilm formation with a focus on fungal biofilms. We will delve into the details of some novel micro- and nanotechnology approaches that have been developed to combat biofilms and the possibility of utilizing them in a clinical setting.


Asunto(s)
Antifúngicos , Materiales Biocompatibles , Biopelículas , Infección Hospitalaria/terapia , Farmacorresistencia Fúngica/efectos de los fármacos , Hongos , Nanopartículas/uso terapéutico , Antifúngicos/farmacología , Antifúngicos/uso terapéutico , Vendajes , Materiales Biocompatibles/farmacología , Materiales Biocompatibles/uso terapéutico , Biopelículas/efectos de los fármacos , Biopelículas/crecimiento & desarrollo , Hongos/efectos de los fármacos , Hongos/fisiología , Humanos
12.
Lancet ; 393(10167): 183-198, 2019 01 12.
Artículo en Inglés | MEDLINE | ID: mdl-30558872

RESUMEN

Antibiotics are the commonest cause of life-threatening immune-mediated drug reactions that are considered off-target, including anaphylaxis, and organ-specific and severe cutaneous adverse reactions. However, many antibiotic reactions documented as allergies were unknown or not remembered by the patient, cutaneous reactions unrelated to drug hypersensitivity, drug-infection interactions, or drug intolerances. Although such reactions pose negligible risk to patients, they currently represent a global threat to public health. Antibiotic allergy labels result in displacement of first-line therapies for antibiotic prophylaxis and treatment. A penicillin allergy label, in particular, is associated with increased use of broad-spectrum and non-ß-lactam antibiotics, which results in increased adverse events and antibiotic resistance. Most patients labelled as allergic to penicillins are not allergic when appropriately stratified for risk, tested, and re-challenged. Given the public health importance of penicillin allergy, this Review provides a global update on antibiotic allergy epidemiology, classification, mechanisms, and management.


Asunto(s)
Antibacterianos/efectos adversos , Hipersensibilidad a las Drogas , Penicilinas/efectos adversos , Anafilaxia/etiología , Infección Hospitalaria/epidemiología , Infección Hospitalaria/terapia , Hipersensibilidad a las Drogas/clasificación , Hipersensibilidad a las Drogas/diagnóstico , Hipersensibilidad a las Drogas/epidemiología , Hipersensibilidad a las Drogas/terapia , Farmacorresistencia Microbiana , Femenino , Salud Global , Humanos , Masculino , Factores de Riesgo , beta-Lactamasas/efectos adversos
13.
Eur J Clin Microbiol Infect Dis ; 39(10): 1933-1939, 2020 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-32504314

RESUMEN

The MODIFY I/II trials demonstrated that bezlotoxumab, a human monoclonal antibody against Clostridioides difficile toxin B, given during antibiotic treatment for Clostridioides difficile infection (CDI) significantly reduced C. difficile recurrence (rCDI) in adults at high risk for rCDI. Efficacy of CDI-directed intervention may depend on ribotype regional epidemiology, and patient characteristics. This post hoc analysis assessed the efficacy of bezlotoxumab in the subgroup of MODIFY I/II trial participants enrolled in Europe. Data from the bezlotoxumab (10 mg/kg single intravenous infusion) and placebo (0.9% saline) groups from MODIFY I/II were compared to assess initial clinical cure (ICC), rCDI, all-cause, and CDI-associated rehospitalizations within 30 days of discharge, and mortality through 12 weeks post-infusion. Of 1554 worldwide participants, 606 were from Europe (bezlotoxumab n = 313, 51%; placebo n = 292; 48%). Baseline characteristics were generally similar across groups, although there were more immunocompromised participants in the bezlotoxumab group (27.2%) compared with placebo (20.1%). Fifty-five percent of participants were female, and 86% were hospitalized at randomization. The rate of ICC was similar between treatment groups. The rate of rCDI in the bezlotoxumab group was lower compared with placebo among European participants overall, and among those with ≥ 1 risk factor for rCDI. Bezlotoxumab reduced 30-day CDI-associated rehospitalizations compared with placebo. These results are consistent with overall results from the MODIFY trials and demonstrate that bezlotoxumab reduces rCDI and CDI-associated rehospitalizations in European patients with CDI. MODIFY I/II (NCT01241552 and NCT01513239).


Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Anticuerpos ampliamente neutralizantes/uso terapéutico , Infecciones por Clostridium/tratamiento farmacológico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Antibacterianos/administración & dosificación , Antibacterianos/uso terapéutico , Anticuerpos Monoclonales/administración & dosificación , Proteínas Bacterianas/inmunología , Toxinas Bacterianas/inmunología , Anticuerpos ampliamente neutralizantes/administración & dosificación , Infecciones por Clostridium/mortalidad , Infección Hospitalaria/mortalidad , Infección Hospitalaria/terapia , Combinación de Medicamentos , Europa (Continente) , Femenino , Humanos , Infusiones Intravenosas , Masculino , Persona de Mediana Edad , Ensayos Clínicos Controlados Aleatorios como Asunto , Adulto Joven
14.
Circ J ; 84(4): 670-676, 2020 03 25.
Artículo en Inglés | MEDLINE | ID: mdl-32132310

RESUMEN

BACKGROUND: Healthcare-associated infective endocarditis (HAIE) has become increasingly recognized worldwide because the underlying patient conditions are completely different from those of community-acquired infective endocarditis (CIE). However, data on HAIE in the Japanese population is lacking. We sought to clarify the patient characteristics and prognosis of HAIE in a Japanese population.Methods and Results:A retrospective study was conducted in 158 patients who were diagnosed with infective endocarditis, 53 of whom (33.5%) were classified as HAIE. Compared with patients with CIE, those with HAIE were older (median age 72 vs. 61 years; P=0.0002) and received surgical treatment less frequently (41.5% vs. 62.9%; P=0.01). Regarding causative microorganisms, staphylococci,including methicillin-resistant pathogens, were more common in patients with HAIE (32.1% vs. 14.3%; P=0.01). Patients with HAIE had higher in-hospital mortality (32.1% vs. 4.8%; P<0.0001) and Kaplan-Meier analysis showed worse prognosis for patients with HAIE than CIE (P<0.0001, log-rank test). On multivariate Cox analysis, HAIE (hazard ratio 3.26; 95% confidence interval 1.49-7.14), age ≥60 years, surgical treatment, stroke, and heart failure were independently associated with mortality. CONCLUSIONS: HAIE has different clinical characteristics and causative microorganisms, as well as worse prognosis, than CIE. Preventive strategies, and the prompt and appropriate identification of HAIE may improve the outcome of infective endocarditis.


Asunto(s)
Infecciones Comunitarias Adquiridas , Infección Hospitalaria , Endocarditis , Centros de Atención Terciaria , Adulto , Anciano , Infecciones Comunitarias Adquiridas/diagnóstico por imagen , Infecciones Comunitarias Adquiridas/microbiología , Infecciones Comunitarias Adquiridas/mortalidad , Infecciones Comunitarias Adquiridas/terapia , Comorbilidad , Infección Hospitalaria/diagnóstico por imagen , Infección Hospitalaria/microbiología , Infección Hospitalaria/mortalidad , Infección Hospitalaria/terapia , Endocarditis/diagnóstico por imagen , Endocarditis/microbiología , Endocarditis/mortalidad , Endocarditis/terapia , Femenino , Mortalidad Hospitalaria , Humanos , Masculino , Persona de Mediana Edad , Pronóstico , Estudios Retrospectivos , Medición de Riesgo , Factores de Riesgo , Factores de Tiempo
15.
Transpl Infect Dis ; 22(6): e13364, 2020 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-32521074

RESUMEN

Solid organ transplant recipients are considered at high risk for COVID-19 infection due to chronic immune suppression; little data currently exists on the manifestations and outcomes of COVID-19 infection in lung transplant recipients. Here we report 8 cases of COVID-19 identified in patients with a history of lung transplant. We describe the clinical course of disease as well as preexisting characteristics of these patients.


Asunto(s)
COVID-19/fisiopatología , Infección Hospitalaria/fisiopatología , Inmunosupresores/uso terapéutico , Trasplante de Pulmón , Adenosina Monofosfato/análogos & derivados , Adenosina Monofosfato/uso terapéutico , Adulto , Anciano , Alanina/análogos & derivados , Alanina/uso terapéutico , Anticuerpos Monoclonales Humanizados/uso terapéutico , Antivirales/uso terapéutico , COVID-19/diagnóstico por imagen , COVID-19/inmunología , COVID-19/terapia , Tos/fisiopatología , Infección Hospitalaria/diagnóstico por imagen , Infección Hospitalaria/inmunología , Infección Hospitalaria/terapia , Fibrosis Quística/cirugía , Disnea/fisiopatología , Femenino , Fiebre/fisiopatología , Enfermedades Gastrointestinales/fisiopatología , Glucocorticoides/uso terapéutico , Rechazo de Injerto/prevención & control , Humanos , Fibrosis Pulmonar Idiopática/cirugía , Inmunoglobulinas Intravenosas/uso terapéutico , Factores Inmunológicos/uso terapéutico , Proteína Antagonista del Receptor de Interleucina 1/uso terapéutico , Pulmón/diagnóstico por imagen , Masculino , Metilprednisolona/uso terapéutico , Persona de Mediana Edad , Pancreatitis Aguda Necrotizante , Enfermedad Pulmonar Obstructiva Crónica/cirugía , Quimioterapia por Pulso , SARS-CoV-2 , Sepsis , Índice de Severidad de la Enfermedad , Tomografía Computarizada por Rayos X
16.
Z Gastroenterol ; 58(9): 855-867, 2020 Sep.
Artículo en Alemán | MEDLINE | ID: mdl-32947631

RESUMEN

BACKGROUND: The economic effects of spontaneous bacterial peritonitis (SBP), nosocomial infections (nosInf) and acute-on-chronic liver failure (ACLF) have so far been poorly studied. We analyzed the impact of these complications on treatment revenues in hospitalized patients with decompensated cirrhosis. METHODS: 371 consecutive patients with decompensated liver cirrhosis, who received a paracentesis between 2012 and 2016, were included retrospectively. DRG (diagnosis-related group), "ZE/NUB" (additional charges/new examination/treatment methods), medication costs, length of hospital stay as well as different kinds of specific treatments (e. g., dialysis) were considered. Exclusion criteria included any kind of malignancy, a history of organ transplantation and/or missing accounting data. RESULTS: Total treatment costs (DRG + ZE/NUB) were higher in those with nosInf (€â€Š10,653 vs. €â€Š5,611, p < 0.0001) driven by a longer hospital stay (23 d vs. 12 d, p < 0.0001). Of note, revenues per day were not different (€â€Š473 vs. €â€Š488, p = 0.98) despite a far more complicated treatment with a more frequent need for dialysis (p < 0.0001) and high-complex care (p = 0.0002). Similarly, SBP was associated with higher total revenues (€â€Š10,307 vs. €â€Š6,659, p < 0.0001). However, the far higher effort for the care of SBP patients resulted in lower daily revenues compared to patients without SBP (€â€Š443 vs. €â€Š499, p = 0.18). ACLF increased treatment revenues to €â€Š10,593 vs. €6,369 without ACLF (p < 0.0001). While treatment of ACLF was more complicated, revenue per day was not different to no-ACLF patients (€â€Š483 vs. €â€Š480, p = 0.29). CONCLUSION: SBP, nosInf and/or ACLF lead to a significant increase in the effort, revenue and duration in the treatment of patients with cirrhosis. The lower daily revenue, despite a much more complex therapy, might indicate that these complications are not yet sufficiently considered in the German DRG system.


Asunto(s)
Insuficiencia Hepática Crónica Agudizada/economía , Infecciones Bacterianas/economía , Infección Hospitalaria/economía , Grupos Diagnósticos Relacionados/economía , Costos de la Atención en Salud/estadística & datos numéricos , Peritonitis/economía , Insuficiencia Hepática Crónica Agudizada/terapia , Infecciones Bacterianas/terapia , Infección Hospitalaria/complicaciones , Infección Hospitalaria/terapia , Grupos Diagnósticos Relacionados/estadística & datos numéricos , Alemania/epidemiología , Humanos , Tiempo de Internación , Cirrosis Hepática/complicaciones , Peritonitis/tratamiento farmacológico , Estudios Retrospectivos
17.
Asia Pac J Clin Nutr ; 29(2): 280-287, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32674236

RESUMEN

BACKGROUND AND OBJECTIVES: The optimal energy intake for early nutrition therapy in critically ill patients is unknown, especially in Chinese patients with a lower BMI. This study investigated the relationship between energy intake and clinical outcomes in this patient population. METHODS AND STUDY DESIGN: A retrospective study was carried out at a tertiary hospital. Critically ill patients were recruited and divided into 3 tertiles according to the ratio of actual/target energy intake during the first week of hospitalization in the intensive care unit (ICU) (tertile I, <33.4%; tertile II, 33.4%-66.7%; and tertile III, >66.7%). 60-day mortality and other clinical outcomes were compared. To adjust for potentially confounding factors, multivariate and sensitivity analyses were performed exclusively in patients who stayed in the ICU for ≥7 days. RESULTS: A total of 325 patients with a mean BMI of 22.5±4.7 kg/m2 were recruited. 60-day mortality was similar between the 3 tertiles. In the unadjusted analysis, tertile III had a longer length of stay in the ICU and at the hospital, longer duration of mechanical ventilation, and higher rate of ICU-associated infections, but only the latter showed a significant difference between the 3 tertiles in the multivariate and sensitivity analyses. Logistic regression analysis showed that energy groups was an independent risk factor for ICU-associated infections. CONCLUSIONS: Energy intake in early nutrition therapy influences risk of ICU-associated infections in Chinese critically ill patients with lower BMI. Furthermore, patients with near-target energy intake have more frequent ICU-associated infections.


Asunto(s)
Enfermedad Crítica , Infección Hospitalaria/epidemiología , Estado Nutricional , Apoyo Nutricional , Índice de Masa Corporal , China , Infección Hospitalaria/etiología , Infección Hospitalaria/prevención & control , Infección Hospitalaria/terapia , Femenino , Humanos , Unidades de Cuidados Intensivos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Centros de Atención Terciaria , Pérdida de Peso
18.
Encephale ; 46(3S): S99-S106, 2020 Jun.
Artículo en Francés | MEDLINE | ID: mdl-32405083

RESUMEN

COVID-19 is a multi-organ disease due to an infection with the SARS-CoV2 virus. It has become a pandemic in early 2020. The disease appears less devastating in children and adolescents. However, stress, quarantine and eventually mourning have major impacts on development. It is difficult to describe what this pandemic implies for a child psychiatrist, other than by giving a first-hand account. I propose to go through the main ethical questions that have arisen; to describe how my hospital team has reorganized itself to meet the new demands and questions, in particular by opening a unit dedicated to people with autism and challenging behaviors affected by COVID-19; and to address, in a context of national discussion, how the discipline has sought to understand the conditions of a certain well-being during quarantine. Finally, I will try to conclude with more speculative reflections on re-opening.


Asunto(s)
Psiquiatría del Adolescente , Actitud del Personal de Salud , Trastorno Autístico/terapia , Betacoronavirus , Psiquiatría Infantil , Infecciones por Coronavirus , Pandemias , Neumonía Viral , Psiquiatría , Adolescente , Conducta del Adolescente , Psiquiatría del Adolescente/ética , Trastorno Autístico/complicaciones , Trastorno Autístico/psicología , COVID-19 , Niño , Conducta Infantil , Psiquiatría Infantil/ética , Control de Enfermedades Transmisibles/métodos , Infecciones por Coronavirus/complicaciones , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/prevención & control , Infecciones por Coronavirus/psicología , Infecciones por Coronavirus/transmisión , Infección Hospitalaria/complicaciones , Infección Hospitalaria/psicología , Infección Hospitalaria/terapia , Exposición a Riesgos Ambientales , Francia , Accesibilidad a los Servicios de Salud , Reestructuración Hospitalaria , Unidades Hospitalarias/organización & administración , Humanos , Control de Infecciones/métodos , Servicios de Salud Mental/ética , Servicios de Salud Mental/organización & administración , Trastornos del Olfato/etiología , Trastornos del Olfato/psicología , Pandemias/prevención & control , Aceptación de la Atención de Salud , Grupo de Atención al Paciente , Aislamiento de Pacientes/psicología , Ludoterapia , Neumonía Viral/complicaciones , Neumonía Viral/prevención & control , Neumonía Viral/psicología , Neumonía Viral/transmisión , Práctica Profesional/ética , Equipos de Seguridad , Factores de Riesgo , SARS-CoV-2 , Estrés Psicológico/etiología
19.
Przegl Epidemiol ; 74(1): 23-31, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32500981

RESUMEN

BACKGROUND: After the introduction of rotavirus vaccines into immunization schedules, noroviruses account for the majority of acute gastrointestinal infections. The aim of the study was to assess the clinical presentation in immunocompromised and immunocompetent children with hospital- and community-acquired norovirus gastroenteritis. MATERIAL AND METHODS: We retrospectively reviewed clinical records of children with noroviral gastroenteritis, hospitalized in the Pediatric Hospital, Medical University of Warsaw, between 2015 and 2018. Acute gastrointestinal tract symptoms and confirmed etiology of noroviral infection were inclusion criteria. The analysis was performed in the subgroups of immunocompetent and immunocompromised patients, during community-acquired and nosocomial infections. RESULTS: A total of 57 children with median age 1.5 year (IQR: 0.7-4.0) were recruited. The majority of patients were immunocompetent (87.7%), and nosocomial infections were predominant (56.1%). Gastrointestinal symptoms included nausea, vomiting and diarrhoea (in approximately 85%), while systemic manifestations such as fever and malaise where observed in only ». Routine laboratory tests were normal in most of the patients. An analysis in the subgroups revealed statistically significant differences in blood pH and serum electrolyte levels - acidosis and electrolyte disturbances were statistically significantly more common in immunocompromised vs immunocompetent patients (p<0.05). CONCLUSIONS: More frequently the clinical presentation includes gastrointestinal symptoms with no differences between immunocompromised and immunocompetent hosts. The median laboratory values were normal in generally healthy children; disturbances were observed only in children with immunodeficiencies. Therefore, prophylactic measures are of particular importance in the latter group, which is especially sensitive to severe and nosocomial infections.


Asunto(s)
Infecciones por Caliciviridae/terapia , Infecciones Comunitarias Adquiridas/terapia , Infección Hospitalaria/terapia , Infecciones por Caliciviridae/epidemiología , Niño , Preescolar , Infecciones Comunitarias Adquiridas/epidemiología , Infección Hospitalaria/epidemiología , Femenino , Humanos , Huésped Inmunocomprometido , Lactante , Masculino , Norovirus
20.
Cancer ; 125(9): 1404-1409, 2019 05 01.
Artículo en Inglés | MEDLINE | ID: mdl-30695098

RESUMEN

Plans to optimize health care in the United States highlight the high cost but rarely explore opportunities for redirecting resources within the existing system to increase access to care while lowering spending. This analysis indicates that, of the total national health care expenditures of $3.21 trillion in 2015, only $1.4 trillion to $2.86 trillion was used to provide care to patients. This range was reached by the subtraction of excess spending in 7 categories. Thus, many opportunities exist to repurpose wasted expenditures to increase access to health care without the need for additional funding.


Asunto(s)
Atención a la Salud/economía , Atención a la Salud/estadística & datos numéricos , Gastos en Salud/estadística & datos numéricos , Calidad de la Atención de Salud/economía , Ahorro de Costo , Análisis Costo-Beneficio , Infección Hospitalaria/economía , Infección Hospitalaria/epidemiología , Infección Hospitalaria/terapia , Atención a la Salud/organización & administración , Eficiencia Organizacional/economía , Femenino , Fraude/economía , Fraude/estadística & datos numéricos , Costos de la Atención en Salud/estadística & datos numéricos , Mal Uso de los Servicios de Salud/economía , Mal Uso de los Servicios de Salud/estadística & datos numéricos , Humanos , Cobertura del Seguro/economía , Cobertura del Seguro/estadística & datos numéricos , Masculino , Errores Médicos/economía , Errores Médicos/estadística & datos numéricos , Calidad de la Atención de Salud/estadística & datos numéricos , Estados Unidos/epidemiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA